ABOUT this BLOG and How to use it

WELCOME to Stu's Views & MS News, a product of MS Views and News, a Not-for-Profit 501(c3) organization. Founded in 2008. Providing Educational, Information and Resources to those affected by Multiple Sclerosis via live seminars and via the internet.

Key-Note: Our live MS educational seminars average approx 65 people per educational program and SINCE our first program in February 2010, we have hosted more than 90 educational programs in Florida. In 2013 we expanded to Georgia and in 2014 we have expanded into Alabama and North Carolina.

Register at our website to receive our globally transmitted Multiple Sclerosis e-newsletter, currently being received in more than (90) Countries. Visit MS Views and News.org

Scroll to view All the resources found on the left side of this blog. Need to find information, use our 'search by topic' tool.

Be Empowered with MS News and Information


Wednesday, April 23, 2014

Currently we have over 7700 Signatures for Lemtrada Petition which is closing on April 30th

We seek an FDA reversal on their December 30, 2013 decision to NOT approve Sanofi’s Lemtrada, a Multiple Sclerosis Treatment. Patients needs this Medication-option Approved
There are currently 7,770 signatures

PETITION BACKGROUND Thousands of Multiple Sclerosis patients are getting worse each day, when currently used medications are not working for them or their body refuses to accept the medication. 

Another Option is needed and this Option Should be Lemtrada 

The FDA on December 30, 2013 Denies the use of Lemtrada for MS Patients. THIS was A sad day for people with more active Multiple Sclerosis. 

Lemtrada has been approved worldwide, but not good enough for us it seems, in the USA. 

We are more than 400,000 strong (living with MS) in the USA 
WE NEED YOUR VOTE to give another OPTION to those that Can benefit from this medication; hoping to keep them from severe disability. 

Also we need you to write directly. WE NEED YOU TO send emails. – 
We need this request to go Viral -- 

In the middle of March, we submitted 5001 signatures to the FDA by postal mail and via email.

After we close the petition of April 30th, we will submit the final numbers
THIS IS why, for those that have not yet signed this petition, we ask you to consider again, asking the FDA about CHOICE... 
Providing another Choice



Data from Genzyme's Multiple Sclerosis Franchise Featured at AAN

- Aubagio(R) and Lemtrada(TM) Results To Be Highlighted -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 22, 2014-- 
Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that 18 poster and oral presentations featuring Aubagio(R) (teriflunomide) and Lemtrada(TM) (alemtuzumab) will be presented during the 66th American Academy of Neurology (AAN) Annual Meeting to be held in Philadelphia, April 26 -- May 3, 2014.
"As we continue to expand our global footprint in MS with product launches planned in more than 30 countries this year, we are proud to highlight the breadth and depth of our clinical development programs for Aubagio and Lemtrada at AAN," said David Meeker, President and CEO, Genzyme. "These new data will help to build a deeper understanding of MS and Genzyme's treatments, and demonstrate our long-term commitment to meeting the needs of people living with MS."
Presentations on Aubagio and Lemtrada at AAN are as follows, along with information about the Genzyme Corporate Therapeutic Update and Brain Health Fair sponsorship.
   -- TOPIC: Efficacy and Safety of Once-Daily Oral Teriflunomide in Patients 
      with First Clinical Episode Consistent With Multiple Sclerosis (Clinical 
      Trials Plenary Session; May 2; 12:00 -- 1:30 p.m. EDT) 
   -- Teriflunomide Does Not Significantly Affect Primary and Memory Antibody 
      Responses to a Viral Antigen in Mice (Poster Session I -- P1.215; April 
      28; 3:00 p.m. EDT) 
   -- Teriflunomide Treatment Is Not Associated With Increased Risk of 
      Infections: Pooled Data From the Teriflunomide Development Program 
      (Poster Session II -- P2.194; April 29; 7:30 a.m. EDT) 
   -- Pooled Safety Data From Four Placebo-Controlled Teriflunomide Studies 
      (Poster Session II -- P2.203; April 29; 7:30 a.m. EDT) 
   -- Teriflunomide: Non-Clinical Evaluation Demonstrates No Effect On Sperm 
      DNA or Male Fertility (Poster Session II -- P2.233; April 29; 7:30 a.m. 
   -- Safety and Efficacy of Teriflunomide for up to 9 Years in Relapsing Forms 
      of Multiple Sclerosis: Update of the TEMSO Extension Trial (Poster 
      Session III -- P3.150; April 29; 3:00 p.m. EDT) 
   -- Patients Free of Clinical MS Activity in TEMSO and TOWER: Pooled Analyses 
      of Two Phase 3 Placebo-Controlled Trials (Poster Session III -- P3.164; 
      April 29; 3:00 p.m. EDT) 
   -- Updated Pregnancy Outcomes in Patients and Partners of Patients in the 
      Teriflunomide Clinical Trial Program (Poser Session IV -- P4.161; April 
      30; 7:30 a.m. EDT) 
   -- Estimating the Onset of Efficacy With Teriflunomide in Patients With 
      Relapsing Forms of Multiple Sclerosis (Poster Session VII -- P7.214; May 
      1; 3:00 p.m. EDT) 

-- Treatment with Anti-mouse CD52 Antibody Is Associated with Preservation
      of Myelin and Maintenance of Axonal Conduction in the MOG-induced EAE 
      Mouse Model (Poster Session I -- P1.220; April 28; 3:00 p.m. EDT) 
   -- Anti-murine CD52 Antibody Treatment Does Not Adversely Affect the 
      Migratory Ability of Immune Cells (Poster Session I -- P1.222; April 28; 
      3:00 p.m. EDT) 
   -- Successful Detection and Management of Immune Thrombocytopenia in 
      Alemtuzumab-Treated Patients with Active Relapsing-Remitting Multiple 
      Sclerosis (Poster Session II -- P2.198; April 29; 7:30 a.m. EDT) 
   -- Thyroid Autoimmune Adverse Events in Patients Treated with Alemtuzumab 
      for Relapsing-remitting Multiple Sclerosis: Four-year Follow-up of the 
      CARE-MS Studies (Poster Session II -- P2.199; April 29; 7:30 a.m. EDT) 
   -- Safety of Using Disease-modifying Therapy Post-alemtuzumab Treatment in 
      Patients With Relapsing-remitting Multiple Sclerosis in the Core and 
      Extension Phases of CAMMS223, CARE-MS I, and CARE-MS II Studies (Poster 
      Session II -- P2.201; April 29; 7:30 a.m. EDT) 
   -- Alemtuzumab Has Similar Efficacy and Safety in Active Relapsing-Remitting 
      Multiple Sclerosis (RRMS) Patients Who Were Treatment-Naive or Who 
      Relapsed on Prior Therapy (Poster Session II -- P2.209; April 29; 7:30 
      a.m. EDT) 
   -- Alemtuzumab Improves Visual Outcomes vs. Subcutaneous Interferon Beta-1a 
      in Patients With Active Relapsing-Remitting Multiple Sclerosis (RRMS) Who 
      Relapsed on Prior Therapy: Analysis From the CARE-MS II Study (Poster 
      Session III -- P3.158; April 29; 3:00 p.m. EDT; INS 7 Poster Rounds: 
      Emerging Therapeutic Advances in Multiple Sclerosis -- I7-1.010; April 
      30; 4:30 p.m. EDT) 
   -- Sustained Improvement in Disability Outcomes with Alemtuzumab in Active 
      Relapsing-Remitting Multiple Sclerosis Patients Who Participated in 
      CARE-MS II: Three-year Follow-up (Poster Session III -- P3.165; April 29; 
      3:00 p.m. EDT) 
   -- Lymphocyte Counts Do Not Predict Risk of Subsequent Relapse or Disability 
      Accumulation in Alemtuzumab-Treated Relapsing-Remitting Multiple 
      Sclerosis Patients: An Analysis of the CARE-MS Studies (Poster Session 
      III -- P3.181; April 29; 3:00 p.m. EDT) 
Abstracts are available on the AAN website.
Genzyme Corporate Therapeutic Update
"The Evolving Paradigm: Individualizing MS Care"
When: Tuesday, April 29; 7:00 -- 8:30 p.m. EDT
Location: Sheraton Philadelphia Downtown Hotel, Liberty Ballroom (201 N 17th Street, Philadelphia)
Brain Health Fair
Genzyme is proud to serve as a silver sponsor of this year's Brain Health Fair, taking place on Saturday, April 26. The Brain Health Fair, presented by the American Brain Foundation, the foundation of the American Academy of Neurology, is a free event that is open to the public and designed to help connect patients, families and caregivers affected by neurologic disorders.
About Aubagio(R) (teriflunomide)
Aubagio is approved in the United States, European Union, Australia, Argentina, Brazil, Canada, Chile, Columbia, Mexico, New Zealand, South Korea and Switzerland, with additional marketing applications under review by regulatory authorities globally.
Aubagio is an immunomodulator with anti-inflammatory properties. Although the exact mechanism of action for Aubagio is not fully understood, it may involve a reduction in the number of activated lymphocytes in the central nervous system (CNS). Aubagio is supported by one of the largest clinical programs of any MS therapy, with more than 5,000 trial participants in 36 countries. Some patients in extension trials have been treated for up to 10 years.
About Lemtrada(TM) (alemtuzumab)
Lemtrada is approved in the European Union, Australia, Brazil, Canada and Mexico. Lemtrada is currently not approved in the United States. Following constructive discussions with the FDA, Genzyme plans to resubmit in the second quarter of 2014 its application seeking U.S. approval of Lemtrada. The resubmission will provide information to specifically address issues previously noted by the FDA in its December 2013 Complete Response Letter. Marketing applications for Lemtrada are also under review in other countries. Lemtrada is supported by a comprehensive and extensive clinical development program that involved nearly 1,500 patients and 5,400 patient-years of follow-up.
Alemtuzumab is a monoclonal antibody that selectively targets CD52, a protein abundant on T and B cells. Treatment with alemtuzumab results in the depletion of circulating T and B cells thought to be responsible for the damaging inflammatory process in MS. Alemtuzumab has minimal impact on other immune cells. The acute anti-inflammatory effect of alemtuzumab is immediately followed by the onset of a distinctive pattern of T and B cell repopulation that continues over time, rebalancing the immune system in a way that potentially reduces MS disease activity.
Genzyme holds the worldwide rights to alemtuzumab and has primary responsibility for its development and commercialization in multiple sclerosis. Bayer HealthCare holds the right to co-promote alemtuzumab in MS in the United States. Upon commercialization, Bayer will receive contingent payments based on global sales revenue.
READ About Genzyme, a Sanofi Company


To comment - click the comment link shown below
Share our Articles with others
Sign-up at:  www.msviewsandnews.org 
To Keep CURRENT  and up to date with MS News and Information
Donate Now Please - Click here
Thank you    

Tuesday, April 22, 2014

Cooling Products might prevent you from over-heating

Cooling Products might prevent you from over-heating, might prevent you from feeling sluggish or event might prevent you from feeling crummy. Rises in body temperature often make you symptomatic. 

Cooling Products might enable you to feel ENERGIZED! 

Look at the Polar Products shown here.
See what these might do to benefit you, with the coming summer heat.


To comment - click the comment link shown below
Share our Articles with others
Sign-up at:  www.msviewsandnews.org 
To Keep CURRENT  and up to date with MS News and Information

Thank you    

New Multiple Sclerosis Drug Delivery Device Focuses On Easy, User-Friendly Design

For Extavia Injections

ExtaviPro® 30G auto-injectorUK-based product development and consultancy firm Cambridge Consultants, in association with Swiss pharma giants Novartis and medical device manufacturers Owen Mumford, have introduced a new injective drug delivery system for the subcutaneous administration of drugs (e.g.: interferon beta-1b) in patients with Multiple Sclerosis (MS), known as the ExtaviPro® 30G auto-injector.
MS is a progressive neurodegenerative disorder which causes inflammation and subsequent damage to the insulatory myelin sheaths that protect the neurons and are vital in transfer of nerve impulses within the central nervous system (CNS). The disease directly affects the brain and spinal cord, leading to vision problems, mental disorders, failure to maintain balance, dizziness, and a host of other symptoms, which prove to be fatal in later stages. Most people experience the first bouts of failure of conduction of nerve impulses and indications of demylination of neurons (also known as Clinically Isolated Syndrome or CIS), followed by “flare-ups” (relapse), which lead to a reappearance of symptoms and exacerbation after a period of comparatively normal health (remission) — a stage of the disease known as Relapsing-Remitting Multiple Sclerosis, or RRMS. In turn, RRMS often leads to progressive worsening of symptoms and deterioration of health (a condition called Secondary-Progressive Multiple Sclerosis or SPMS). Multiple Sclerosis is the cause of mortality among almost 2.5 million people worldwide, being more common in women than men.
The ExtaviPro® 30G auto-injector is designed to facilitate Interferon beta-1b drug delivery for Multiple Sclerosis patients who are still at the relapsing stage of the disease, The new drug delivery device is innovative in that it balances the amount of pro- and anti-inflammatory cells in the CNS and helps to reduce the number of immune cells crossing the blood-brain barrier, thus enhancing the survival potential of nerve fibers. A group of more than 500 patients and healthcare professionals from throughout the United States, United Kingdom, and mainland Europe have participated in the development of the device.
Previously, surveys had been conducted to check patient satisfaction with the use of injection devices (according to reports published in the September and November 2013 issues of the online journals Pragmatic and Observational Research Medical Devices: Evidence and Research, both belonging to DovePress), which yielded positive feedback overall. The device has been designed specifically to facilitate single-handed injection with an adjustable needle-depth and ergonomic design to foster patient compliance. The instruction leaflet has also been carefully written to make the directions for using the device more user-friendly. Traveling with the device is easy as well, as it includes a travel case that allows all of the components to be stored in one central, compact container.
Continue reading of this Auto-injector, here


To comment - click the comment link shown below
Share our Articles with others
Sign-up at:  www.msviewsandnews.org 
To Keep CURRENT  and up to date with MS News and Information

Thank you    

Monday, April 21, 2014

Supreme Court declines to block ruling on multiple sclerosis drug in patent dispute

Article by: SAM HANANEL , Associated Press Updated: April 18, 2014 - 4:16 PM

WASHINGTON — Supreme Court Chief Justice John Roberts on Friday declined to temporarily block a lower court ruling that opens the world's best-selling multiple sclerosis drug to competition from generic rivals next month.
The decision is a victory for rivals challenging the patents of Israel-based Teva Pharmaceutical Industries Ltd., maker of the drug Copaxone.
Teva claims the U.S. Court of Appeals for the Federal Circuit wrongly overturned five of its patents for the drug. That ruling allows rivals Mylan Inc., Momenta Pharmaceuticals Inc. and Sandoz, Inc., to start selling cheaper generic versions in May instead of September 2015.
The Supreme Court has agreed to consider the case, but arguments won't take place until its new term begins in October and it could be next year before a decision is reached. Teva said it would suffer irreparable harm if the appeals court decision was not postponed. Copaxone brought the company $3.2 billion in U.S. sales last year.
In a one-page ruling, Roberts said he was not convinced Teva would suffer such harm. If Teva ultimately prevails in the case, Roberts said, the company would be able to recover damages from the generic rivals for past patent infringement. He acknowledged that Teva has "a fair prospect" of ultimately winning the case at the high court.
Roberts oversees emergency appeals from the U.S. Court of Appeals for the Federal Circuit, which hears appeals in patent cases.
It is the second time Roberts has declined to put the appeals court ruling on hold. He rejected a similar request from Teva in November while the high court was deciding whether to take up the appeal.
The rival companies had argued that granting a stay would effectively extend Teva's monopoly for years to come. That's because Teva is trying to switch existing Copaxone patients to a new formulation of the drug that has patent protection until 2030


To comment - click the comment link shown below
Share our Articles with others
Sign-up at:  www.msviewsandnews.org 
To Keep CURRENT  and up to date with MS News and Information
Donate Now Please - Click here
Thank you    

MS Healthfair - Saturday May 10th in Carmel, In. -One Day Can Make a difference for those affected by MS





The One Day for Every Day event for people
with relapsing MS and their care partners.

SATURDAY, MAY 10, 2014

Get information from MS experts, learn about an oral treatment option,
and connect with the community.
Breakfast and lunch will be served.
Free parking is available.
We hope you’ll join us.

MS EXPERT PANEL: A neurologist, people living with MS, and others will
discuss MS and a treatment option, and answer questions – so bring

WORKSHOPS: Join 1 of 3 different sessions led by experts:
· Effectively Communicate Your MS Story
· Make Technology Work for You
· MS and Your Relationships

MS HEALTH FAIR: Organizations, companies, and support groups
devoted to people living with MS will be on hand to talk, share, and

Renaissance Indianapolis North Hotel
11925 N. Meridian Street
Carmel, IN 46032

SATURDAY, MAY 10, 2014
11:00 AM – 2:00 PM
(Registration and MS Health Fair open at 10:00 AM)

GO TO 1day4everyday.com  - OR CALL 1-866-703-6293 TODAY


Sunday, April 20, 2014

Myelin Update: Researchers present new view of myelin

Date: April 18, 2014
Source: Harvard University

Neuroscientists have made a discovery that turns 160 years of neuroanatomy on its head. Myelin, the electrical insulating material long known to be essential for the fast transmission of impulses along the axons of nerve cells, is not as ubiquitous as thought, according to a new work. "The fact that it is the most evolved neurons, the ones that have expanded dramatically in humans, suggests that what we're seeing might be the "future." As neuronal diversity increases and the brain needs to process more and more complex information, neurons change the way they use myelin to "achieve" more," says the main researcher.

This is a computer image of three neurons showing differences in myelin.
Credit: Daniel Berger and Giulio Tomassy/Harvard University
Harvard neuroscientists have made a discovery that turns 160 years of neuroanatomy on its head.
Myelin, the electrical insulating material long known to be essential for the fast transmission of impulses along the axons of nerve cells, is not as ubiquitous as thought, according to a new work lead by Professor Paola Arlotta of the Harvard Stem Cell Institute (HSCI) and the University's Department of Stem Cell and Regenerative Biology, in collaboration with Professor Jeff Lichtman, of Harvard's Department of Molecular and Cellular Biology.
"Myelin is a relatively recent invention during evolution," says Arlotta. "It's thought that myelin allowed the brain to communicate really fast to the far reaches of the body, and that it has endowed the brain with the capacity to compute higher level functions." In fact, loss of myelin is a feature of a number of devastating diseases, including multiple sclerosis and schizophrenia.
But the new research shows that despite myelin essential roles in the brain, "some of the most evolved, most complex neurons of the nervous system have less myelin than older, more ancestral ones" Arlotta, co-director of the HSCI neuroscience program, says.
What this means, Arlotta says, is that the higher in the cerebral cortex one looks -- the closer to the top of the brain, which is its most evolved region -- the less myelin one finds. Not only that, but "neurons in this part of the brain display a brand new way of positioning myelin along their axons that has not been previously seen. They have 'intermittent myelin' with long axon tracts that lack myelin interspersed among myelin-rich segments.
Arlotta continues: "contrary to the common assumptions that neurons use a universal profile of myelin distribution on their axons, the work indicate that different neurons choose to myelinate their axons differently. In classic neurobiology textbooks myelin is represented on axons as a sequence of myelinated segments separated by very short nodes that lack myelin. This distribution of myelin was tacitly assumed to be always the same, on every neuron, from the beginning to the end of the axon. This new work finds this not to be the case."
The results of the research by Arlotta and post doctoral fellow Giulio Srubek Tomassy, the first author on the report, are published in the latest edition of Science, the journal of the American Association for the Advancement of Science.
The paper is accompanied by a "Perspective" by R. Douglas Fields, of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, at the National Institutes of Health, who says that Arlotta and Tomassy's findings raise important questions about the purpose of myelin, "are likely to spark new concepts about how information is transmitted and integrated in the brain."
Arlotta and Tomassy collaborated closely on the new work with postdoctoral fellow Daniel Berger of the Lichtman group, which generated one of the two massive electron microscopy data bases that made the work possible.


To comment - click the comment link shown below
Share our Articles with others
Sign-up at:  www.msviewsandnews.org 
To Keep CURRENT  and up to date with MS News and Information
Donate Now Please - Click here
Thank you    

Multiple sclerosis on the rise in the UAE (United Arab Emirates)

Multiple sclerosis on the rise in the UAEPhoto Credit:REUTERS/Michael Buholzer
Friday, Apr 18, 2014

Dubai: Multiple sclerosis (MS) is on the rise in the UAE, according to a survey by the MS International Federation.
Figures reveal that there were nearly 1,500 MS patients in the UAE last year, while in 2008 the number stood at 219.
Dr Suzann Nori, consultant neurologist at the Rashid Hospital , Dubai believes the spike in cases of the auto-immune disease, which damages the brain and spinal cord resulting in symptoms including dizziness, fatigue and numbness, may be due to improved monitoring and awareness of the condition.
“The rise in the numbers can be attributed to the increasing investigative measures being undertaken in this country,” she said. “People are more aware of the disease and its symptoms. There are more doctors now than in 2008, with increased availability of MRIs, which are necessary to detect the disease. The increasing number of immigrants to this country also attributes to the rise.”
The condition has a higher incidence of occurrence among UAE nationals. A 2011 study conducted by Dr Jihad Inshasi, Consultant Neurologist at Rashid Hospital , DHA, in Dubai, highlighted that out of the 284 MS patients identified, 158 (55.6 per cent) were UAE nationals while 126 (44.4 per cent) were immigrants. Among UAE nationals, the female to male ratio was 2.85:1, suggesting that females were at a higher risk of contracting the disease.
Another problem is that patients remain reluctant to come out in the open about their condition because of the fear of isolation or stigma, which makes ealy diagnosis more difficult.
“The cause for the onset of the disease has not yet been identified, hence we cannot identify the preventive or protective measures,” said Dr Nori. “Identifying the early symptoms of the disease and proper treatment can help control disease progression and also prevent complications.”
But while the disease is not curable, Dr Nori stressed that proper medication can help to slow the disease.
“We often tell patients to avoid heat to prevent attacks,” she said. “In food options, we recommend consumption of Omega 3-6-9, which is common in fish, and avoiding red meat.”
One of the most disturbing factors is funding the cost of the treatment. Most insurance companies do not foot the bill for MS treatment, which can be anywhere between Dh5,000 and Dh13,000 per month.
By Suchitra Bajpai Chaudhary Senior Reporter
Gulf News 2014. All rights reserved.


To comment - click the comment link shown below
Share our Articles with others
Sign-up at:  www.msviewsandnews.org 
To Keep CURRENT  and up to date with MS News and Information
Donate Now Please - Click here
Thank you    

Ed J. - is Raising Dollars for MS Research

Okay here it is.I hope it is something that you can help me with? Yes, ALL of You... You can all help... 

Have you or a loved one been diagnosed with Multiple Sclerosis? It sucks, right? You want to scream, don’t you? 

Ed Johnson sure did. 

For more than 20 years, Ed was a College volleyball coach and the ultimate physical specimen -- well, until. He was diagnosed with Progressive MS in 2006 and a year later was bound to a wheelchair. 

MS is BS is his way to channel the anger that comes before acceptance into something positive: irreverent t-shirts, koozies. stickers and more. Products that allow catharsis and raise money for MS research. 

Please Visit MStshirts.org

Ed Johnson


Disclaimer: Stu's Views & MS News / MS Views and News, is not responsible for the wording or the content that comes from the above website.
However, we do ask you to take a look at Ed'd site


Join us for another Fun Day - Fundraiser to benefit those affected by MS


TICKETS on sale now 

Join us for an Evening at the

Who:    Nick Dipaolo, Comedian
What:   Comedy Club Fundraiser for MS Views and News
Where:  IMPROV Comedy Club – at Hard Rock Casino
              5700 Seminole Way - Hollywood, Fl.

When:   Saturday, June 14, 2014

Why:     Because we want to see YOU and we want you to Laugh!!

Doors open: 6 PM
Start Time:  7 PM

Entrance Requirements:  21 years or older

with a 2 drink minimum purchase ( alcoholic or non-alcoholic)
Ticket Cost:  $15 for one; $25 for two

Register Securely, Online by clicking here  
or visiting www.events.msvn.org 

or Contact for tickets or information:  
Jill - jill@msvn.org  (203) 550-7703
 or Carri - chic68@bellsouth.net

"MS Views and News" (MSVN) is a 501©(3) Not For Profit organization as recognized by the Internal Revenue Service

ALL proceeds from this event will benefit MS educational programs


Friday, April 18, 2014

Apr 12, 2014 from Birmingham, Alabama - Drs. Chris LaGanke and Rupa Kitchens - speak about Treatments, Symptoms and Bladder

https://www.youtube.com/watch?v=9TcYSmA4Tbg --

MS can be a Fatal Disease - says Dr. LaGanke

Listen to this for a little while, then pause and then get back to it later on --

Listen with Dr. Chris LaGanke - Neurologist speak about Treatments, Relapse, Symptoms and more - then hear Dr. Rupa Kitchens -Urologist speak about BLADDER ISSUES --

-- Learn and share this with others --



To comment - click the comment link shown below
Share our Articles with others
Sign-up at:  www.msviewsandnews.org 
To Keep CURRENT  and up to date with MS News and Information
Donate Now Please - Click here
Thank you